Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma

Patients with metastatic or unresectable (advanced) pheochromocytoma and paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter, phase 2 trial evaluated the efficacy and safety of high-specific-activity (131)I-meta-iodobenzylguanidine (HSA (131)I-MIBG) in patients with...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Nucl Med
Päätekijät: Pryma, Daniel A., Chin, Bennett B., Noto, Richard B., Dillon, Joseph S., Perkins, Stephanie, Solnes, Lilja, Kostakoglu, Lale, Serafini, Aldo N., Pampaloni, Miguel H., Jensen, Jessica, Armor, Thomas, Lin, Tess, White, Theresa, Stambler, Nancy, Apfel, Stuart, DiPippo, Vincent A., Mahmood, Syed, Wong, Vivien, Jimenez, Camilo
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Society of Nuclear Medicine 2019
Aiheet:
Theranostics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6495236/
https://ncbi.nlm.nih.gov/pubmed/30291194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.118.217463
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia